DiaMedica Therapeutics (DMAC) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
DiaMedica Therapeutics (DMAC) has outperformed ARS Pharmaceuticals (SPRY) over the past year, gaining 16.5% versus a loss of 57.8%. Over five years, DMAC leads with a +94.9% price change compared with -55.8% for SPRY. ARS Pharmaceuticals is the larger company by market cap ($433.6 million vs $430.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMAC | SPRY |
|---|---|---|
| Share price | $7.99 | $4.36 |
| Market cap | $430.87M | $433.59M |
| 1-day change | -1.72% | +1.51% |
| YTD return | +0.38% | -62.58% |
| 1-year return | +16.47% | -57.79% |
| 5-year return | +94.88% | -55.78% |
| EPS (TTM) | $-0.72 | $-2.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.42 | $13.15 |
| 52-week low | $5.25 | $3.99 |
| Distance from 52-week high | -23.32% | -66.84% |
| Average volume | 177.47K | 1.86M |
| Shares outstanding | 53.93M | 99.45M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMAC has outperformed SPRY by 74.3 percentage points over the past year.
DMAC vs SPRY FAQ
Which is bigger, DiaMedica Therapeutics or ARS Pharmaceuticals?
ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $433.59M compared with $430.87M for DiaMedica Therapeutics (DMAC).
Which stock has performed better over the past year, DMAC or SPRY?
DMAC returned +16.47% over the past 12 months, compared with -57.79% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are DiaMedica Therapeutics and ARS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.